IL221271A - Selective reduction of allele variants - Google Patents

Selective reduction of allele variants

Info

Publication number
IL221271A
IL221271A IL221271A IL22127112A IL221271A IL 221271 A IL221271 A IL 221271A IL 221271 A IL221271 A IL 221271A IL 22127112 A IL22127112 A IL 22127112A IL 221271 A IL221271 A IL 221271A
Authority
IL
Israel
Prior art keywords
allelic variants
selective reduction
selective
reduction
allelic
Prior art date
Application number
IL221271A
Other languages
English (en)
Hebrew (he)
Other versions
IL221271A0 (en
Original Assignee
Ionis Pharmaceuticals Inc
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44356119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL221271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ionis Pharmaceuticals Inc, Univ British Columbia filed Critical Ionis Pharmaceuticals Inc
Publication of IL221271A0 publication Critical patent/IL221271A0/en
Publication of IL221271A publication Critical patent/IL221271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL221271A 2010-02-08 2012-08-02 Selective reduction of allele variants IL221271A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30245810P 2010-02-08 2010-02-08
US37164010P 2010-08-06 2010-08-06
PCT/US2011/024104 WO2011097644A2 (fr) 2010-02-08 2011-02-08 Réduction sélective de variants alléliques

Publications (2)

Publication Number Publication Date
IL221271A0 IL221271A0 (en) 2012-10-31
IL221271A true IL221271A (en) 2017-04-30

Family

ID=44356119

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221271A IL221271A (en) 2010-02-08 2012-08-02 Selective reduction of allele variants

Country Status (7)

Country Link
US (4) US9006198B2 (fr)
EP (3) EP2534262B1 (fr)
JP (1) JP6018506B2 (fr)
AU (1) AU2011213563B2 (fr)
CA (1) CA2789038A1 (fr)
IL (1) IL221271A (fr)
WO (1) WO2011097644A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370451B1 (fr) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Procédé pour la synthèse d'acides nucléiques modifiés au niveau de l'atome de phosphore
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
JP6006120B2 (ja) * 2010-02-08 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
EP2620428B1 (fr) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
EP3467109A1 (fr) * 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9914922B2 (en) 2012-04-20 2018-03-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
EP2872485B1 (fr) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
WO2014059353A2 (fr) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Composés oligomères comportant des nucléosides bicycliques et leurs utilisations
EP2906255B1 (fr) * 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Composés anti-sens et leurs utilisations
EP2906256B1 (fr) * 2012-10-12 2018-08-22 Ionis Pharmaceuticals, Inc. Composés anti-sens sélectifs et leurs utilisations
CA2899924A1 (fr) * 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Composes antisens selectifs et leurs utilisations
EP3008201B1 (fr) 2013-06-12 2019-08-07 The General Hospital Corporation Procédés pour détection multiplexe de molécules cibles et leurs utilisations
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108048A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
CA2936712A1 (fr) 2014-01-16 2015-07-23 Meena Conception chirale
KR20170069262A (ko) * 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017100726A1 (fr) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Méthodes de traitement de la maladie de huntington
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
CA3066224A1 (fr) 2017-06-05 2018-12-13 Ptc Therapeutics Inc. Composes permettant de traiter la maladie de huntington
EP3645121A4 (fr) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. Méthodes de traitement de la maladie de huntington
EP3644996B1 (fr) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Procédés de traitement de la maladie de huntington
SG11202000274RA (en) * 2017-08-08 2020-02-27 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
US20210009590A1 (en) 2018-03-27 2021-01-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3814357B1 (fr) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Composés hétérocycliques et hétéroaryles pour le traitement de la maladie de huntington
MA54875A (fr) * 2019-02-01 2021-12-08 Wave Life Sciences Ltd Compositions oligonucléotidiques et procédés associés
BR112022007947A2 (pt) 2019-11-01 2022-07-12 Novartis Ag Uso de modulador de splicing para tratamento que retarda a progressão da doença de huntington
US20220251557A1 (en) * 2019-11-27 2022-08-11 Tokyo Institute Of Technology Method for reducing toxicity of antisense nucleic acids
CN115885042A (zh) 2020-05-22 2023-03-31 波涛生命科学有限公司 双链寡核苷酸组合物及其相关方法
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1994014226A1 (fr) 1992-12-14 1994-06-23 Honeywell Inc. Systeme de moteur a tolerance de pannes
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6753422B2 (en) * 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2363077A1 (fr) 1999-03-01 2000-09-08 Variagenics, Inc. Methodes permettant de cibler des molecules d'arn
EP1178999B1 (fr) 1999-05-04 2007-03-14 Santaris Pharma A/S Analogues de l-ribo-lna
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU4819101A (en) 2000-04-13 2001-10-30 University Of British Columbia, The Modulating cell survival by modulating huntingtin function
EP1499627A2 (fr) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Oligonucleotides chimeres resistants a la nuclease
US20030109476A1 (en) 2001-08-07 2003-06-12 Kmiec Eric B. Compositions and methods for the prevention and treatment of Huntington's disease
WO2004044136A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
WO2004041889A2 (fr) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
WO2005027962A1 (fr) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides et composes d'oligomeres
US20050176045A1 (en) * 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
AU2005252662B2 (en) * 2004-06-03 2011-08-18 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
JP2008513507A (ja) * 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド 増強されたアンチセンスオリゴヌクレオチド
ATE522626T1 (de) 2005-06-28 2011-09-15 Medtronic Inc Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
AU2007210038B2 (en) * 2006-01-26 2013-01-10 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
DK2458006T3 (en) * 2006-05-05 2018-08-27 Ionis Pharmaceuticals Inc Compounds and Methods for Modulating ApoB Expression.
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
US9273356B2 (en) * 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
CA2662704A1 (fr) * 2006-07-07 2008-01-10 University Of Massachusetts Compositions de silencage de l'arn, et methodes de traitement de la choree de huntington
EP3202905A1 (fr) 2006-10-18 2017-08-09 Ionis Pharmaceuticals, Inc. Composés antisens
AU2007325767A1 (en) 2006-11-27 2008-06-05 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2125852B1 (fr) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. Nucléosides modifiés 5'-substitués-2'-f et composés oligomères préparés à partir de ceux-ci
WO2008143774A2 (fr) 2007-05-01 2008-11-27 University Of Massachusetts Procédés et compositions permettant de déterminer l'hétérozygocité snp dans le cadre d'un diagnostic et d'une thérapie allèle-spécifiques
EP2170917B1 (fr) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
DE602007005629D1 (de) 2007-06-18 2010-05-12 Commissariat Energie Atomique Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
CA2726866A1 (fr) 2008-05-09 2009-11-12 The University Of British Columbia Procedes et compositions pour le traitement de la maladie de huntington
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
US9778706B2 (en) 2012-02-24 2017-10-03 Blackberry Limited Peekable user interface on a portable electronic device
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping

Also Published As

Publication number Publication date
WO2011097644A2 (fr) 2011-08-11
JP6018506B2 (ja) 2016-11-02
US9006198B2 (en) 2015-04-14
EP2534262A2 (fr) 2012-12-19
EP3628750A1 (fr) 2020-04-01
IL221271A0 (en) 2012-10-31
US20200377946A1 (en) 2020-12-03
EP3208347A1 (fr) 2017-08-23
US20150292015A1 (en) 2015-10-15
US20180291453A1 (en) 2018-10-11
CA2789038A1 (fr) 2011-08-11
WO2011097644A3 (fr) 2011-09-29
JP2013518605A (ja) 2013-05-23
EP2534262A4 (fr) 2013-10-16
AU2011213563B2 (en) 2015-12-24
US20130046008A1 (en) 2013-02-21
EP3208347B1 (fr) 2019-08-14
EP2534262B1 (fr) 2016-12-14
AU2011213563A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
IL254191A0 (en) Selective reduction of allelic variants
IL221271A0 (en) Selective reduction of allelic variants
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
ZA201304280B (en) Treatment of jak2-mediated conditions
PL2652193T3 (pl) Obróbka
HK1183626A1 (en) Keloid treatment
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
EP2560677A4 (fr) Traitement du rhume
GB2481800B (en) Karabiner
GB201013573D0 (en) Treatment
GB201002673D0 (en) Antimicrobial agent
TWM390860U (en) Structure of granulator
GB201014097D0 (en) Treatment
TWM388240U (en) Earring structure
GB201002167D0 (en) Concept seven
TWM389317U (en) Personal effects alarm
TWM390349U (en) Structure of door-in-door
TWM386865U (en) Residue-filtering structure of juice-extractor
TWM390745U (en) Structure improvement of tea-making can
HU1000688D0 (en) Use of trifluoro-phal
GB201021319D0 (en) Treatment
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
GB201003727D0 (en) Therapeutic agent
GB201015144D0 (en) Animal enclosure-sound reduction

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed